Hao Chi Zhang, MD

UT MD Anderson Cancer Center

Poster(s):

• A0540 - Tocilizumab as an Effective Steroid-Sparing Agent for the Treatment of Recurrent and Steroid-Dependent Immune Checkpoint Inhibitor-Mediated Hepatotoxicity: A Case Study and Insight into Pathophysiology
  Sunday, October 23, 2022

  5:00 PM – 7:00 PM ET

• A0541 - Early Use of Tocilizumab as an Effective Steroid-Sparing Strategy for the Treatment of Immune Checkpoint Inhibitor-Mediated Cholangiopathy: Building Foundations for Personalized Management
  Sunday, October 23, 2022

  5:00 PM – 7:00 PM ET